Bausch + Lomb (NYSE:BLCO) Stock: Insider Frederick Munsch Sells 112,015 Shares

Bausch + Lomb Corporation (NYSE:BLCO) CAO Frederick Munsch sold 112,015 shares of Bausch + Lomb stock in a transaction dated Thursday, October 29th. The stock was sold at an average price of $20.48, for a total value of $2,294,067.20. Following the completion of the transaction, the chief accounting officer directly owned 45,831 shares of the company’s stock, valued at approximately $938,618.88. This represents a 70.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Frederick Munsch also recently made the following trade(s):

• On Monday, August 10th, Frederick Munsch sold 52,900 shares of Bausch + Lomb stock. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00.

Bausch + Lomb Stock Performance

Shares of BLCO stock opened at $20.01 on Wednesday. Bausch + Lomb Corporation has a one year low of $14.44 and a one year high of $21.36. The company’s 50-day moving average is $17.46 and its 200 day moving average is $16.71. The company has a market capitalization of $7.15 billion, a price-to-earnings ratio of -64.55, a price-to-earnings-growth ratio of 0.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.04 and a current ratio of 1.56.

Bausch + Lomb (NYSE:BLCO) last released its quarterly earnings data on Wednesday, October 28th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.13. The business had revenue of $1.38 billion during the quarter, compared to analyst estimates of $1.37 billion. Bausch + Lomb had a negative net margin of 2.05% and a positive return on equity of 5.01%. Bausch + Lomb’s revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business earned $0.18 EPS. Sell-side analysts expect that Bausch + Lomb Corporation will post 0.94 EPS for the current fiscal year.

Institutional Trading of Bausch + Lomb

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Whitebox Advisors LLC raised its stake in shares of Bausch + Lomb by 15.8% in the first quarter. Whitebox Advisors LLC now owns 1,101,854 shares of the company’s stock worth $17,519,000 after buying an additional 150,641 shares during the period. Beach Point Capital Management LP bought a new position in shares of Bausch + Lomb during the 3rd quarter valued at approximately $5,882,000. Sei Investments Co. grew its stake in shares of Bausch + Lomb by 100.0% during the 1st quarter. Sei Investments Co. now owns 139,266 shares of the company’s stock valued at $2,214,000 after acquiring an additional 69,633 shares during the period. Engineers Gate Manager LP purchased a new stake in Bausch + Lomb in the 2nd quarter worth approximately $1,479,000. Finally, Dimensional Fund Advisors LP increased its holdings in Bausch + Lomb by 13.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 85,779 shares of the company’s stock worth $1,362,000 after acquiring an additional 9,971 shares in the last quarter. Hedge funds and other institutional investors own 11.07% of the company’s stock.

Analysts Set New Price Targets

BLCO has been the subject of several analyst reports. Zacks Research raised shares of Bausch + Lomb from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 30th. JPMorgan Chase & Co. upped their price objective on Bausch + Lomb from $16.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, October 29th. Leerink Partners assumed coverage on Bausch + Lomb in a research report on Wednesday, September 9th. They issued an “outperform” rating and a $24.00 price objective on the stock. Citigroup increased their target price on Bausch + Lomb from $21.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, October 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a report on Tuesday, September 15th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bausch + Lomb currently has an average rating of “Hold” and an average price target of $20.83.

Trending Headlines about Bausch + Lomb

Here are the key news stories impacting Bausch + Lomb this week:

• Positive Sentiment: Higher earnings estimates: HC Wainwright raised its 2027 EPS forecasts to $0.16 for Q1 (from $0.12) and $0.29 for Q2 (from $0.25), signaling improved expectations for future results. The analyst nevertheless maintains a Neutral rating. HC Wainwright estimate update
• Positive Sentiment: Favorable quantitative rankings: Zacks added BLCO to its Rank #1 (Strong Buy) lists, including its momentum-stock list, and highlighted it as a potential long-term value stock. These assessments may support investor interest, though they are not company-specific operating announcements. Zacks Strong Buy list Zacks value-stock analysis
• Neutral Sentiment: Downgrade paired with a higher target: HC Wainwright cut its rating from Buy to Neutral while raising its price target from $21 to $22. The higher target suggests some expected upside, but the rating change indicates reduced conviction in outperformance. HC Wainwright rating and target update
• Negative Sentiment: Large CAO share sale: Chief Accounting Officer Frederick Munsch sold 112,015 shares for about $2.29 million, reducing his ownership by roughly 71%. The sale may weigh on sentiment, although insider transactions can occur for personal financial reasons. Details of the insider sale

Bausch + Lomb Company Profile

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.